Core Insights - Pzena Investment Management's third-quarter 2025 commentary indicates a strong performance in US broad-based indexes driven by optimism about AI and a September rate cut, with the technology sector outperforming value stocks [1] - The Pzena Focused Value strategy returned 1.1% gross and 0.9% net, underperforming the Russell 1000 Value Index which returned 5.3% [1] Company Overview: Baxter International Inc. (NYSE:BAX) - Baxter International Inc. is a healthcare company with a market capitalization of $9.335 billion, and its stock closed at $18.48 per share on December 09, 2025 [2] - The stock experienced a one-month return of -2.89% and a significant decline of 41.42% over the last 52 weeks [2] Performance Analysis - Baxter's disappointing performance in the third quarter was attributed to a voluntary recall of a recent product launch and a slower-than-expected recovery in demand for IV fluids, which were disrupted by Hurricane Helene [3] - Despite these challenges, the Pzena Focused Value Strategy views the stock price reaction as disproportionate and has increased its position in Baxter [3] Hedge Fund Interest - Baxter International Inc. was held by 38 hedge fund portfolios at the end of the third quarter, an increase from 31 in the previous quarter [4] - While Baxter is recognized for its potential, analysts suggest that certain AI stocks may offer greater upside potential with less downside risk [4] Market Sentiment - The SCCM Enhanced Equity Income Fund divested its stake in Baxter during Q3 2025, indicating a shift in investment strategy among some funds [5]

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Baxter's product, the Novum LVP, had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [2] - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [2] - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [2] - The lawsuit suggests that there was an increased risk of customers being instructed to take Novum LVPs out of service and that Baxter would halt all new sales of these pumps [2] - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [2] Group 2: Next Steps for Investors - Investors who suffered losses in Baxter International, Inc. during the specified timeframe have until December 15, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Insights - Baxter International Inc. is currently among the Top 15 Lowest P/E Ratios of the S&P 500 for 2025, indicating a potentially undervalued stock [1] - Analysts have a consensus Hold recommendation for Baxter, with a one-year average share price target of $23.80, suggesting an upside potential of 28% [4] Financial Adjustments - Morgan Stanley analyst Patrick Wood has reduced the price target for Baxter from $19 to $15 while maintaining an Underweight rating [1] - Argus Research downgraded Baxter on October 31, citing a significant dividend reduction expected to drive an annual cash flow boost of $300 million or more, aimed at strengthening the balance sheet [3] Market Position and Performance - The company is well-positioned in the medical technology sector due to favorable trends in hospital spending and key product launches [2] - Baxter's stock has faced challenges, declining 36% year to date [4] - Concerns have been raised regarding the weak outlook for Baxter's IV fluid solutions business [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, of the December 15, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Baxter common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6] - A lead plaintiff must file a motion with the Court by December 15, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4] Group 3: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients [5] - Specific issues included malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, which Baxter was aware of but did not adequately address [5] - The lawsuit claims that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, resulting in investor damages when the truth was revealed [5]

Core Viewpoint - Baxter International Inc. is facing a federal securities class action lawsuit due to allegations of making false and misleading statements regarding the safety and efficacy of its Novum LVP product, which has been linked to serious patient risks [4][5]. Group 1: Legal Proceedings - Faruqi & Faruqi, LLP is investigating potential claims against Baxter and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in the class action lawsuit [2]. - The lawsuit alleges that Baxter and its executives violated federal securities laws by failing to disclose systemic defects in the Novum LVP, which led to malfunctions and risks to patient safety [4]. - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, and any member can move to serve as lead plaintiff [6]. Group 2: Financial Impact - The true extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary pause in shipments and installations of the Novum LVP, resulting in a 22.4% drop in stock price, closing at $21.76 [5]. - Baxter was reportedly aware of multiple device malfunctions and injuries related to the Novum LVP but failed to take adequate remedial measures [4]. Group 3: Company Background - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995 and has offices in New York, Pennsylvania, California, and Georgia [3]. - The firm encourages anyone with information regarding Baxter's conduct to come forward, including whistleblowers and former employees [7].

NEW YORK, Dec. 5, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Baxter International Inc. (NYSE: BAX) between February 23, 2022 and July 30, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.So what: If you purchased Baxter common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Baxter International, Inc. ("Baxter International, Inc." or the "Company") (NYSE: BAX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Baxter International, Inc. investors who were adversely affected by alleged securities fraud between February 23, 2022 and July 30, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk. ...

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (a) the Novum LVP suffered systemic defects that caused widespread malfunctions, ...

Core Insights - The SCCM Enhanced Equity Income Fund reported a composite return of 0.9% in Q3 2025, underperforming compared to the S&P 500 Buy-Write Index which returned 3.5% [1] - Baxter International Inc. (NYSE:BAX) was highlighted as a significant stock, with a one-month return of 2.67% and a 52-week gain of 41.89% [2] - The fund exited its position in Baxter due to ongoing challenges, including a 40% dividend cut and operational issues, despite recognizing its long-term recovery potential [3] Fund Performance - The S&P 500 returned 8.1% in Q3 2025, while the Russell 1000 Value increased by 5.3% [1] - The fund's performance was notably lower than the S&P 500 Buy-Write Index, which returned 3.5% [1] Baxter International Inc. Analysis - Baxter's stock closed at $18.48 on December 4, 2025, with a market capitalization of $9.5 billion [2] - The company faced significant challenges post-COVID, including margin pressure and pricing issues from hospital Group Purchasing Organizations [3] - Management's decision to cut the dividend by 40% and change the CEO indicates ongoing financial struggles [3] Hedge Fund Interest - Baxter International Inc. was held by 38 hedge fund portfolios at the end of Q3 2025, an increase from 31 in the previous quarter [4] - Despite its potential, analysts suggest that certain AI stocks may offer better investment opportunities with less risk [4]

NEW YORK  , Dec. 4, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Baxter International, Inc. (NYSE: BAX).Shareholders who purchased shares of BAX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/baxter-international-inc-loss-submission-form-2/?id=179558&from=4CLASS PERIOD: F ...